Umuthi wokuhlola wokuvikela umalaleveva, "iMosquirix", uthole imvume ye-European Medicines Agency ngoLwesihlanu. Owokuqala emhlabeni wezokwelapha noma ngabe i-serum, okwamanje isebenza kuphela.
Lezi yizindaba ezinhle zokuqala futhi ezimnandi kakhulu. NgoLwesihlanu ngoJulayi 24, umuthi wokugomela umalaleveva uthole "umbono omuhle" ku-European Medicines Agency (EMA). Ibizwa nge- "Mosquirix" futhi yadalwa yi-giant eyenza imithi uGlaxoSmithKline (GSK) ukuvikela izingane ezincane, ikakhulu e-Afrika, engcupheni enkulu yalesi sifo. Lesi yisikhathi sokuqala ukuthi umuthi wokugoma wenzelwe ukulwa nesimuncagazi (i-Plasmodium falciparum, igciwane likamalaleveva) hhayi igciwane noma amagciwane.
Qala >> Ukugxila: " I-Malaria ibulala ingane njalo ngemizuzwana engu-30«
Lo "mbono omuhle" awusho ukumakethwa ngokushesha kwe-serum, kepha wenza izindaba ezinhle kakhulu ezigulini, kungukukhanya okuluhlaza okokuqala ngaphambi kokuthola "isincomo" sokusetshenziswa enhlanganweni yomhlaba ezempilo (WHO).
"Unyaka nonyaka, cishe abantu abayizigidi ezingama-200 bathinteka umalaleveva […] I-GSK ibilokhu izama ukwenza lo mgomo iminyaka engamashumi amathathu [….] Lesi isikhathi sokuqala ukuthi kube khona i-serum yokulwa ne-parasite", kusho u-Elisabeth Van Damme, umphathi wezokuxhumana weqembu le-GSK eFrance 000.
"IMINYAKA ENGamashumi AMATHATHU KA-GSK IZAMA UKUTHUTHUKISA LOMUVAVANE" (U-ELISABETH VAN DAMME, GSK)
"Ukuvikelwa okunesizotha"
I-GSK ayihlose ukumaketha ukugonywa kwe-malaria eYurophu, kodwa e-Afrika, ezindaweni ezinomlando kakhulu. Njalo ngonyaka, i-malaria inqanda abantu abangamatshumi amahlanu emhlabeni jikelele, kubandakanya iningi labantu base-Afrika.
Kepha kufanele siqaphele: okwamanje, iMosquirix akuyona ipanacea. "Lo mgomo ukhombisa ukusebenza ngempumelelo [ukuvikela lesi sifo] kuze kufike ku-50%", kucacisa inhloko ye-GSK. Kuthinta kuphela izingane ezisanda kuzalwa ezinamasonto ayisithupha kuya kwayi-6 futhi ukusebenza kwayo kuncipha ngemuva konyaka, kukhumbula i-EMA.
Ukuvikelwa "okunesizotha", ngokusho kwe-EMA, ngakho-ke, kepha ukuvikelwa kuyafana.
Ngesikhathi sokushicilelwa kwale miphumela, uchwepheshe kwezokwelapha ezindaweni ezishisayo, uNick White (Mahidol University, eThailand), wathi: “Ekugcineni sinomuthi wokugomela umalaleveva osebenzayo, kodwa awusebenzi kahle njengoba usebenza. ekuqaleni ngangithemba ”.
"Ngokwayo, iMosquirix ngeke iqede umalaleveva"
"Ngokuya ngemiphumela yocwaningo lokuhlola, ikomidi le-CHMP [EMA's Committee for Medicinal Products for Human Use] liphethe ngokuthi, yize lisebenza kahle, inani lenzuzo / ubungozi beMosquirix belivuna", kugcizelele uLwesihlanu l I-ejensi yaseYurophu ezinze eLondon.
I-GSK, ehlela ukumaketha umuthi wokugoma "ngentengo yezindleko" ngaphandle kokwenza inzuzo, iyabona ukuthi umkhiqizo wayo uwodwa akuyona "impendulo ephelele" emelene nomalaleveva.
Lo muthi wokugoma uzomela "ithuluzi elengeziwe ku-arsenal of war" elwa nomalaleveva (amanetha omiyane, izibulala-zinambuzane, njll.), Ngokwengxenye yakhe kusho uDkt Fatoumata Nafo-Traoré, umqondisi omkhulu wenhlangano yamazwe omelene nomalaleveva "Roll Back Umalaleveva ”. “Ithathwe yodwa […] iMosquirix ngeke iqede umalaleveva”.
Nsuku zonke, izingane ezingaphezu kuka-1 300 zibulawa umalaleveva. Ngokwe-WHO, bangu-627 abantu abashone ngo-000 bebulawa umalaleveva, ikakhulukazi e-Afrika (2013%) futhi ikakhulukazi izingane ezineminyaka engaphansi kwemihlanu (90%).
Nge-AFP
